

3. Mestre TA, Busse M, Davis AM, et al. Rating scales and performance-based measures for assessment of functional ability in Huntington's disease: critique and recommendations. *Mov Disord Clin Pract* 2018;5: 361–372. <https://doi.org/10.1002/mdc3.12617>
4. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3 (updated February 2022). Cochrane, 2022. Available from: www.training.cochrane.org/handbook
5. Aromataris E, Munn Z (Editors). *JBIM Manual for Evidence Synthesis*. JBI, 2020. Available from: <https://synthesismanual.jbi.global>
6. Katzenschlager R, de Bie RMA, Costa J, Sampaio C. MDS Evidence Based Medicine Committee: revision of the methodological process for systematic reviews - adoption of the modified GRADE system Available from: <https://www.movementdisorders.org/MDS-Files1/PDFs/EBMPapers/EBMCommitteeMethodologyUpdateSept2021.pdf>

Diabetes and Neuroaxonal Damage in Parkinson's Disease

We read with interest Uyar and colleagues' recent report on the association between diabetes, nondiabetic elevated glycosylated hemoglobin levels (HbA1c), and neuroaxonal damage in Parkinson's disease (PD) patients from the MARK-PD study.¹ The authors confirmed previously established findings of an inverse association between diabetes and cognitive and motor status. The authors also demonstrated higher serum neurofilament light (NfL) levels (a marker of neuroaxonal damage)² in PD patients with prevalent type 2 diabetes and in PD patients with nondiabetic elevated HbA1c levels. These

associations persisted after adjustment for age, body mass index (BMI), and vascular risk factors (prevalent arterial hypertension, hypercholesterolemia, and history of stroke). We recently noted similar motor and cognitive associations in PD patients with diabetes³ in the Tracking Parkinson's study, although only a nonsignificant trend toward an association in the overall PD cohort between NfL levels and more severe motor and cognitive status at baseline,⁴ which may reflect the reduced disease duration in the Tracking Parkinson's cohort, compared with the MARK-PD cohort.

Considering the authors' novel findings of an association between diabetes and neuroaxonal damage, we explored the relationship between serum NfL and diabetes in our previously defined subgroup of the Tracking Parkinson's study.⁴ The analysis was performed using Stata V.17.0 (Stata, RRID:SCR_012763), and differences were compared using Kruskal–Wallis tests for continuous data and χ^2 tests for categorical data, whereas the association between NfL and diabetes was further explored using univariate and multivariate (age, BMI, and vascular risk factors) linear regression analysis.

Of the 280 patients studied, 29 suffered from prevalent type 2 diabetes. PD-DM patients were older (74.1 years \pm SD 7.7 vs. 68.1 years \pm 8.7, $P < 0.001$), with higher BMIs (31.1 \pm SD [standard deviation] 5.7 vs. 27.1 \pm SD 4.4, $P < 0.001$), whereas a higher proportion had coexistent vascular risk factors than PD patients without diabetes ($P = 0.032$). Serum NfL levels were higher in PD-DM patients (39.5 \pm SD 18.9 vs. 29.6 \pm SD 16.0, $P < 0.001$). Using regression analysis, NfL levels were significantly associated with patients' diabetic status (coefficient: 0.82, 95% CI [confidence interval]: 0.45–1.19, $P < 0.0001$), which persisted (coefficient: 0.52, 95% CI: 0.18–0.86, $P = 0.003$) after adjustment for age, BMI, and vascular risk factors (history of angina, myocardial infarction, stroke, hypertension, and hypercholesterolemia).

Our findings affirm Uyar et al's report of an association between PD-DM and more severe neuroaxonal damage. Furthermore, the data indicate that the more severe phenotype in PD-DM noted to date by several studies is likely to be mediated by additional factors other than vascular risk factor burden that tends to coexist in these cases. T2DM and PD share several pathological processes encompassing neuroinflammation, lysosomal dysfunction, mitochondrial dysfunction, and the development of central insulin resistance that leads to neurodegeneration.⁵ This process is in part mediated by hyperglycemia as demonstrated by the MARK-PD study and its downstream impact on α -synuclein aggregation.⁶ It is also possible that some of the observed associations are explained by diabetic neuropathy, as other peripheral neuropathies are known to increase blood NfL concentrations.⁷ Disentangling the mechanistic factors that contribute to this more rapidly progressive axonal damage is of critical importance in the development of disease-modifying therapies for PD. ■

Acknowledgments: Cohort studies: Tracking Parkinson's is primarily funded and supported by Parkinson's UK. It is also supported by the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network. This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and Cambridge BRC. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation.

© 2022 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

***Correspondence to:** Prof. Thomas Foltynie, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK; E-mail: t.foltynie@ucl.ac.uk

Relevant conflicts of interest/financial disclosures: The authors declare that there are no conflicts of interest relevant to this work.

Funding agencies: H.Z. is a Wallenberg scholar supported by grants from the Swedish Research Council (2018-02532); the European Research Council (681712 and 101053962); the Swedish State Support for Clinical Research (ALFGBG-71320); the Alzheimer Drug Discovery Foundation, USA (201809-2016862); the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor, Hjärtfonden, Sweden (FO2019-0228); the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska–Curie grant agreement number 860197 (MIRIADE); the European Union Joint Programme—Neurodegenerative Disease Research (JPN2021-00694); and the UK Dementia Research Institute at UCL (UKDRI-1003). D.G.G. has received grant funding from the Neurosciences Foundation, Michael's Movers, and Parkinson's UK.

Received: 12 April 2022; **Accepted:** 18 April 2022

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29067

Biomarker analysis: Work on the biomarkers of progression in Parkinson's and related disorders is supported by Parkinson's UK and the PSP Association.

This research was funded in whole or in part by Aligning Science Across Parkinson's (grant no.: ASAP-000478) through The Michael J. Fox Foundation for Parkinson's Research. For open access, the author has applied a CC BY public copyright license to all author-accepted manuscripts resulting from this submission.

Nirosen Vijiaratnam, FRCP,¹  Michael Lawton, PhD,^{2,3}
Raquel Real, PhD,^{1,4} Amanda J. Heslegrave, PhD,^{5,6}
Tong Guo, PhD,^{5,6} Dilan Athauda, PhD,¹ 
Sonia Gandhi, PhD,¹ Christine Girges, PhD,¹
Yoav Ben-Shlomo, PhD,³
Henrik Zetterberg, MD, PhD,^{5,6,7,8,9}

Donald G. Grosset, MD,¹⁰ Huw R. Morris, PhD,^{1,4} and
Thomas Foltynie, PhD,^{1*}  PROBaND Clinical Consortium
¹Department of Clinical and Movement Neurosciences, UCL Queen
Square Institute of Neurology, London, United Kingdom, ²School of
Social and Community Medicine, University of Bristol, Bristol,
United Kingdom, ³Department of Social Medicine, University of
Bristol, Bristol, United Kingdom, ⁴Aligning Science Across
Parkinson's (ASAP) Collaborative Research Network, Chevy Chase,
Maryland, USA, ⁵Dementia Research Institute, University College
London, London, United Kingdom, ⁶Department of
Neurodegenerative Disease, UCL Institute of Neurology, Queen
Square, London, United Kingdom, ⁷Clinical Neurochemistry
Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden,
⁸Department of Psychiatry and Neurochemistry, Institute of
Neuroscience and Physiology, The Sahlgrenska Academy at the
University of Gothenburg, Mölndal, Sweden, ⁹Hong Kong Center,
for Neurodegenerative Diseases, Hong Kong, People's Republic of
China, and ¹⁰Department of Neurology, Southern General Hospital,
University of Glasgow and Institute of Neurological Sciences,
Glasgow, United Kingdom

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

1. Uyar M, Lezius S, Buhmann C, et al. Diabetes, glycosylated haemoglobin (HbA1C), and neuroaxonal damage in Parkinson's disease (MARK-PD study). *Mov Disord* 2022;37(6):1299–1304. <https://doi.org/10.1002/mds.29009>
2. Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. *J Neurol Neurosurg Psychiatry* 2019;90:870–881.
3. Athauda D, Evans J, Wernick A, et al. The impact of type 2 diabetes in Parkinson's disease. In submission. *Mov Disord* 2022; in press.
4. Vijiaratnam N, Lawton M, Heslegrave A, et al. Combining biomarkers for prognostic modelling of Parkinson's disease. *J Neurol Neurosurg Psychiatry* Epub ahead of print 2022;0:1–9. <https://doi.org/10.1136/jnnp-2021-328365>
5. Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: a new target for disease modification? *Prog Neurobiol* 2016;145-146:98–120.
6. Vicente Miranda H, Szego ÉM, Oliveira LMA, et al. Glycation potentiates α -synuclein-associated neurodegeneration in synucleinopathies. *Brain* 2017;140:1399–1419.
7. Millere E, Rots D, Simren J, et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-tooth disease. *Eur J Neurol* 2021;28(3):974–981.

Reply to: “Diabetes and Neuroaxonal Damage in Parkinson's Disease”

We appreciate the letter by Vijiaratnam and colleagues, which confirms the association of diabetes with increased neuronal damage in patients with Parkinson's disease (PD) independent of age, body mass index, and vascular risk factors.¹ PD patients with diabetes revealed increased serum neurofilament light (sNfL) chain levels in both the biomarkers in Parkinson's disease (MARK-PD) and Tracking Parkinson's Disease studies.^{1,2} However, disease duration was much longer (12 years vs. 1 year), Hoehn & Yahr stage was more advanced (2.5 vs. 1.8), and Movement Disorder Society–Sponsored Revision of the Unified Parkinson's Disease Rating Scale III score was slightly higher (26 vs. 23) in the MARK-PD study, whereas age and Montreal Cognitive Assessment scores were identical (ie, 68 years and 25 points, respectively).^{1,2} Despite these differences, prevalent diabetes was associated with increased neuronal damage quantified by sNfL in early- and late PD underlining the robustness of this finding. Although sNfL is highly specific for neuronal damage, the underlying neuronal subtype and pathomechanisms leading to neuronal injury are not. In cross-sectional studies, blood NfL was increased not only in PD patients with motor impairment but also in PD patients with cognitive decline, postural instability and gait disorder subtype, and subclinical cardiac damage (ie, troponin and N-terminal brain natriuretic peptide), reflecting different central and peripheral neuronal subtypes.^{3,4} Therefore, findings of increased sNfL in both early and advanced diabetic PD patients, however, might be caused by a different type of neuronal damage involving central dopaminergic or nondopaminergic as well as peripheral motor,

© 2022 International Parkinson and Movement Disorder Society.

***Correspondence to:** Dr. Chi-un Choe, Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinstraße 52, Hamburg 20246, Germany; E-mail: cchoe@uke.de

Jens Kuhle and Chi-un Choe contributed equally to this work.

Funding agencies: Dr. Choe was supported by an Else Kröner Exzellenzstipendium from the Else Kröner-Fresenius Stiftung (grant number: 2018_EKES.04). Dr. Schulz was supported by an Else Kröner Exzellenzstipendium from the Else Kröner-Fresenius Stiftung (grant number: 2020_EKES.16).

Relevant conflicts of interest/financial disclosures: R.S. has nothing to declare. C.B. served on scientific advisory boards for Bial, Desitin, Kyowa Kirin, Merz, Stada Pharm, and Zambon and received honoraria for lectures from AbbVie, Bial, Desitin, TAD Pharma, UCB Pharma, and Zambon. M.P.-N. received lecture fees from AbbVie, Abbott, and Boston Scientific and served as consultant for Medtronic, Boston Scientific, Licher, Zambon, and AbbVie. C.G. reports personal fees from Amgen and personal fees from Boehringer Ingelheim, Novartis, Daiichi Sankyo, Abbott, Prediction Biosciences, and Bayer. J.K. received speaker fees, research support, and travel support from and/or served on advisory boards for the Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Celgene, Merck, Novartis, Octave Bioscience, Roche, and Sanofi. C.-u.C. reports personal fees from Pfizer and Zambon.

Received: 29 April 2022; **Accepted:** 2 May 2022

Published online in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.29064